Abstract
Although the primary thrust of research during clinical development of a new molecular entity is to identify a dosing algorithm for the general patient population, the actual patient population in which the drug will be prescribed after marketing approval is far from homogeneous. The fields of pharmacology, pathology, and pharmacogenetics have made it increasingly clear that within the general patient population there exist sub-populations in which drug disposition as well as drug-receptor expression and activity differ from the population average. Depending on the magnitude of these differences and the width of the therapeutic window between effective and toxic blood concentrations, specific subpopulations might require a dose regimen which diverges from the population average regimen. Unmasking and exploring these special populations during clinical development is one of the focuses of clinical pharmacology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Levy G. Patient-oriented pharmaceutical research: focus on the individual. Pharm Res. 1995;12:943–944.
Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, et al. Assessment and reporting of clinical pharmacology information in drug labeling. Clin Pharmacol Ther. 2000;67:196–200.
Food and Drug Administration. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Fed Register. 1993;58:39406–39416.
European Commission, Enterprise Directorate-General. Notice to applicants: a guideline on summary of product characteristics. 1999.
General requirements on content and format of labeling for human prescription drugs (revised 1 April 2001). US Code Fed Regul. 21:201.56.
Shirkey H. Editorial comment: therapeutic orphans. J Pediatrics. 1968;72:119–120.
Food and Drug Administration. Pediatric exclusivity provision: status report to Congress. 2001.http://www.fda.gov/cder/pediatric/reportcong01.pdf
Kearns GL. Introduction: drug development for infants and children: rescuing the therapeutic orphan. Drug Inform J. 1996;30:1121–1123.
Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104:585–590.
Roberts R, Maldonado S. FDA center for drug evaluation and research (CDER) pediatric plan and new regulations. Drug Inform J. 1996;30:1125–1127.
Milne CP. Pediatric research: coming of age in the new millennium. Am J Ther. 1999;6:263–282.
Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs; revision of “pediatric use” subsection in the labeling: final rule. Fed Register. 1994;59:64240–64250.
Food and Drug Administration. Pediatric patients: regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products: proposed rule. Fed Register. 1997;62:43899–43916.
Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients: final rule. Fed Register. 1998;63:66632–66671.
European Commission, Enterprise Directorate-General. Better medicines for children: proposed regulatory actions on paediatric medicinal products, consultation document. 2002.
Food and Drug Administration. General considerations for the clinical evaluation of drugs in infants and children. 1977.
American Academy of Pediatrics Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric patients. Pediatrics. 1995;95(2):286–294.
Food and Drug Administration. Guidance for industry: the content and format for pediatric use supplements. 1996.
Food and Drug Administration. Draft guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. 1998.
Food and Drug Administration. Qualifying for pediatric exclusivity under section 505A of the Federal Food, Drug, and Cosmetic Act. 1999.
International Conference on Harmonization. Guidance for industry El 1: clinical investigations of medicinal products in pediatric populations. 2000.
Cohen SN. Pediatric pharmacology research unit (PPRU) network and its role in meeting pediatric labeling needs. Pediatrics. 1999;104:644–645.
Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet. 1989;17(Suppl 1):29–67.
Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol. 2000;106:S128–S138.
Reed MD. Ontogeny of drug disposition: focus on drug absorption, distribution, and excretion. Drug Inform J. 1996;30:1129–1134.
Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet. 1989;17(Suppl 1):13–28.
Zenk KE. Challenges in providing pharmaceutical care to pediatric patients. Am J Hosp Pharm. 1994;51:688–694.
Leeder JS, Keams GL. Pharmacogenetics in pediatrics: implications for practice. Ped Clin North Am. 1997;44:55–77.
Rane A. Phenotyping of drug metabolism in infants and children: potentials and problems. Pediatrics. 1999;104:640–643.
Ptachcinski RJ, Burckart GJ, Rosenthal JT. Cyclosporine pharmacokinetics in children following cadaveric renal transplantation. Transplant Proc. 1986;18:766.
Dunn S, Cooney G, Sommeraurer J, Lindsay C, McDiarmid S, Wong RL, et al. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients. Transplantation. 1997;63:1762–1767.
Kovarik JM, Mueller EA, Niese D. Clinical development of a cyclosporine microemulsion in transplantation. Ther Drug Monit. 1996;18:429–434.
McRorie T. Quality drug therapy in children: formulations and delivery. Drug Inform J. 1996;30:1173–1177.
Nahata MC. Lack of pediatric drug formulations. Pediatrics. 1999;104:607–609.
American Academy of Pediatrics Committee on Drugs. “Inactive” ingredients in pharmaceutical products: update. Pediatrics. 1997;99:268–278.
Autret E. European regulatory authorities and pediatric labeling. Pediatrics. 1999;104:614–618.
Reed MD. Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics. 1999;104:627–632.
Collart L, Blaschke TF, Boucher F, Prober CG. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Devel Pharmacol Ther. 1992;18:71–80.
Kauffman RE, Keams GL. Pharmacokinetic studies in paediatric patients: clinical and ethical considerations. Clin Pharmacokinet. 1992;23:10–29.
Kovarik JM, Kahan BD, Rajagopalan PR, Bennett W, Mulloy LL, Gerbeau C, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. Transplantation. 1999;68:1288–1294.
Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation. (in press).
Kovarik JM, Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation. (in press).
Simulect (basiliximab). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company; 2001. p. 2218–2220.
Food and Drug Administration. Guidance for industry: population pharmacokinetics. 1999.
Pamis SJ, Foate JA, van der Walt JH, Short T, Crowe CE. Oral midazolam is an effective premedication for children having day-stay anaesthesia. Anaesth Intensive Care. 1992;20:9–14.
Reed MJ, Rodarte A, Blumer JL, Khoo KC, Akbari B, Pou S, et al. Single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol. 2001;41:1359–1369.
Marshall J, Rodarte A, Blumer JL, Khoo KC, Akbari B, Kearns GL and the Pediatric Pharmacology Research Unit Network. Pediatric pharmacodynamics of midazolam. J Clin Pharmacol. 2000;40:578–589.
Versed (midazolam hydrochloride). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company; 2001. p. 2800–2804.
Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet. 1997;33:302–312.
Anonymous. Geriatric study incentives modeled on pediatric patent extensions suggested. The Pink Sheet. 1998;60:11.
Crome P, Flanagan RJ. Pharmacokinetic studies in elderly people: are they necessary? Clin Pharmacokinet. 1994;26:243–247.
Ozdemir V, Fourie J, Busto U, Naranjo CA. Pharmacokinetic changes in the elderly: do they contribute to drug abuse and dependence? Clin Pharmacokinet. 1996;31:372–385.
Tregaskis BF, Stevenson IH. Pharmacokinetics in old age. British Med Bull. 1990;46:9–21.
Maletta G, Mattox KA, Dysken M. Guidelines for prescribing psychoactive drugs in the elderly: part 1. Geriatrics. 1991;46:40–47.
International Conference on Harmonization. Note for guidance on studies in support of special population: geriatrics. 1994.
Food and Drug Administration. Guidance for industry: in vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. 1999.
Exelon (rivastigmine tartrate). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company; 2001. p. 2171–2174.
Food and Drug Administration. Guidance for industry: content and format for geriatric labeling. 2001.
Food and Drug Administration. General considerations for the clinical evaluation of drugs. Publication no. HEW (FDA) 77–3040. Washington, DC: Government Printing Office; 1977.
Food and Drug Administration. Guideline for the format and content of the clinical and statistics sections of new drug applications. 1988.
Kim JS, Nafziger AN. Is it sex or is it gender? Clin Pharmacol Ther. 2000;68:1–3.
Bush JK. Industry perspective on the inclusion of women in clinical trials. Acad Med. 1994;69:708–715.
Chen ML, Williams RL. Women in bioavailability/bioequivalence trials: a regulatory perspective. Drug Inform J. 1995;29:813–820.
Chen ML, Lee SC, Ng MJ, Schuirmann DJ, Lesko LJ, Williams RL. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000;68:510–521.
Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1995;50:222–239.
Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37:529–547.
Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharmacol Ther. 1999;24:339–346.
Merkatz RB, Temple R, Sobel S, Feiden K, Kessler DA. Women in clinical trials of new drugs: a change in Food and Drug Administration policy. N Engl J Med. 1993;329:292–296.
Hartter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit. 1998;20:446–449.
Luvox (fluvoxamine maleate). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company; 2001. p. 3153–3156.
Sekar V, Gobburu J, Chang J, ZumBrunnen T. Population pharmacokinetic modeling to support pediatric use of fluvoxamine. Abstract. J Clin Pharmacol. 2001;41:1021.
Kashuba ADM, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203–218.
Gustayson LE, Benet LZ. Menopause: pharmacodynamics and pharmacokinetics. Exp Gerontol. 1994;29:437–444.
Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, et al. Effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol. 2002;53:67–74.
Xie CX, Piecoro LT, Wermeling DP. Gender-related consideration in clinical pharmacology and drug therapeutics. Crit Care Nurs Clinics of North Am. 1997;9:459–468.
Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet. 1990;18:472–484.
Food and Drug Administration. Draft guidance for industry: combined oral contraceptives-labeling for healthcare providers and patients. 2000.
Food and Drug Administration and the National Institutes of Health Conference. Clinical pharmacology during pregnancy: addressing clinical needs through science. 2000. Conference transcript athttp://www.fda.gov/cder/present/clinpharm2000/1204pregtxt
Food and Drug Administration. Draft guidance for industry: establishing pregnancy registries. 1999.
Murray L, Seger D. Drug therapy during pregnancy and lactation. Emerg Clin North Am. 1994;12:129–149.
Wilson JT, Brown RD, Hinson JL, Dailey JW. Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio from drugs. Ann Rev Pharmacol Toxicol. 1985;25:667–689.
American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137–150.
Breitzka RL, Sandritter TL, Hatzopoulos FK. Principles of drug transfer into breast milk and drug disposition in the nursing infant. J Human Lact. 1997;13:155–158.
Scialli AR. Drugs and lactation: another failure of product labeling. Reproductive Toxicol. 1996;10:91–92.
Shyu WC, Shah VR, Campbell DA, Venitz J, Jaganathan V, Pittman KA, et al. Excretion of cefprozil into human breast milk. Antimicrob Agents Chemother. 1992;36:938–941.
Cefzil (cefprozil). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company; 2001. p. 998–1001.
International Committee on Harmonization. Guidance for industry E5: ethnic factors in the acceptability of foreign clinical data. 1998.
Foster MW, Sharp RR, Mulvihill JJ. Pharmacogenetics, race, and ethnicity: social identities and individualized medical care. Ther Drug Monitor. 2001;23:232–238.
Sheldon TA, Parker H. Race and ethnicity in health research. J Public Health Med. 1992;14:104–110.
Anand SS. Using ethnicity as a classification variable in health research: perpetuating the myth of biological determinism, serving socio-political agendas, or making valuable contributions to medical sciences? Ethnic Health. 1999;4:241–244.
Freeman HP. The meaning of race in science-considerations for cancer research. Cancer. 1998;82:219–225.
Kitler ME. Clinical trials and transethnic pharmacology. Drug Safety. 1994; II:378–391.
Wood AJJ. Ethnic differences in drug disposition. Ther Drug Monit. 1998;20:525–526.
Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol. 2001;41:815–850.
Johnston JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000;38:53–60.
Andersson T, Regàrdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of Smephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics. 1992;2:25–31.
Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther. 1996;60:157–167.
Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates forHelicobacter pyloriinfection and peptic ulcer. Ann Intern Med. 1998;129:1027–1030.
Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52:349–355.
Prilosec (omeprazole). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Cornpany; 2001. p. 587–591.
Van Geerven JMA, Uchida E, Uchida N, Pieters MSM, Meinders AJ, Schoemaker RC, et al. Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. J Clin Pharmacol. 1998;38:1129–1136.
Lam YWF, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet. 1997;32:30–57.
Ibrahim S, Honig P, Huang SM, Gillespie W, Lesko U, Williams RL. Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol. 2000;40:31–38.
Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. 1998.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:3141.
Schwartz GJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984;104:849–854.
Schwartz GJ. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1978;35:53–62.
Lee CS, Marbury TC, Benet LZ. Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm. 1980;8:69–81.
Keller E, Reetze P, Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1990;18:104–117.
Gambertoglio JG. Drug use in renal disease. In: Knoben JE, Anderson PO, eds. Handbook of clinical drug data. Hamilton, IL: Drug Intelligence Publications. 1993. p. 161–170.
Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed. Philadelphia: Lee and Febiger; 1989. p. 238–254.
Lee CC, Marbury TC. Drug therapy in patients undergoing hemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1984;9:42–66.
Boelaert J, Valcke Y, Schurgers M, Daneels R, Rosseneu M, Rosseel MT, Bogeart MG. Pharmacokinetics of ciprofloxacin in patients with impaired renal function. J Antimicrob Chemother. 1985;16:87–93.
Webb DB, Roberts DE, Williams JD, Asscher AW. Pharmacokinetics of ciprofloxacin in healthy volun-teers and patients with impaired kidney function. J Antimicrob Chemother. 1986;18(Suppl D):83–87.
Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP. Pharmacokinetics of ciprofloxacin tablets in renal failure: influence of haemodialysis. Eur J Clin Pharmacol. 1987;31:589–593.
Bergan T, Thorsteinsson SB, Rohwedder R, Scholl H. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function. Chemother. 1989;35:393–405.
Cipro (ciprofloxacin hydrochloride). In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company; 2001. p. 847–852.
Food and Drug Administration. Draft guidance for industry: pharmacokinetics in patients with impaired hepatic function-study design, data analysis, and impact on dosing and labeling. 1999.
Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther. 1989;40:439–474.
McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet. 1991;21:42–69.
Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet. 1999;37:399431.
Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115–121.
Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet. 1995;29:370–391.
Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Safety. 1997;17:47–73.
George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995;21:120–128.
Pugh RNH, Murrary-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg. 1973;60:646–649.
Brockmoller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet. 1994;27:216–248.
Figg WD, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard F, et al. Comparison of quantitative methods to assess hepatic function: Pugh’s classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacother. 1995;15:693–700.
Bergquist C, Lindegard J, Salmonson T. Dosing recommendations in liver disease (Letter to the editor). Clin Pharmacol Ther. 1999;66:201–204.
Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73:920–925.
Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer S, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther. 2001;70:425–430.
Lee PID. Design and power of a population pharmacokinetic study. Pharm Res. 2001;18:75–82.
Lesko LJ, Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2002;2:20–24.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kovarik, J.M. (2004). Special Population Studies In Clinical Development: Pharmacokinetic Considerations. In: Krishna, R. (eds) Applications of Pharmacokinetic Principles in Drug Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9216-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9216-1_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4842-9
Online ISBN: 978-1-4419-9216-1
eBook Packages: Springer Book Archive